Related Experiment Video
Updated: Jan 30, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
Xingming Zhang1,2, Xiaoxue Yin3, Haoran Zhang1,2
1Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan, China.
Background:
Due to the significant heterogeneity of renal cell carcinoma (RCC), immune checkpoints may express differently between primary and metastatic tumor. We aimed to evaluate the differential expression of TIM-3 between the primary and metastatic sites of RCC.
Methods:
Cases of RCC with metastases resected or biopsied at West China Hospital between January 2009 and November 2016 were included. Clinicopathological parameters were retrospectively extracted. SPPS 22.0, GraphPad Prism 6 and R statistical software were applied for data analysis.
Results:
A total of 163 cases were included. Immunohistochemical results showed that the overall detection rate of TIM-3 was 56.4% (92/163). The detection rate of TIM-3 in the primary (53.0%, 44/83) was numerically higher than that of the metastasis (42.6%,79/174). Although the concordance rate of TIM-3 between the primary and metastasis was as high as 66.3% (55/83) in the paired cohort, a significant statistically difference of TIM-3 expression between the primary and metastasis was observed (χ2 = 4.664, p = 0.002), with a poor consistency (Kappa = 0.331, p = 0.002). Subsequent survival analysis suggested that TIM-3 expression either in the primary or metastatic tumor was associated with longer progression-free survival (PFS) (HR: 0.67, 95% CI 0.45-0.99, P = 0.02) and overall survival (OS) (HR: 0.52, 95% CI 0.33-0.82, P < 0.001). The expressions of TIM-3 in the primary, metastatic tumors and patients treated with targeted agents all played as favorable factors for PFS and OS. Further multivariate analysis showed that, in the whole cohort, TIM-3 expression in metastatic tumor increased the predicted accuracy (PA) of the whole model of PFS from 74.7 to 75.6% (P = 0.02). For OS, the PA of whole model was increased from 78.1 to 81.1% by adding TIM-3 expression in the metastasis (P = 0.005). The same trends were also observed in paired patients and patients treated with targeted agents. In conclusion, the expression difference between the primary and metastatic tumor of TIM-3 was significant. Biopsy or resection of the metastases may provide a more accurate biological information for clinician's decision-making and the patient's prognosis. What's more, the role of TIM-3 in the RCC still remains controversy, further study are needed to verify the conclusion.
Insights
Differential expression of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) was observed between primary and metastatic renal cell carcinoma (RCC). TIM-3 expression in metastatic sites provides more accurate prognostic information for patients with RCC.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Renal cell carcinoma (RCC) exhibits significant heterogeneity, potentially leading to differential immune checkpoint expression between primary and metastatic tumors.
- Evaluating T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression differences is crucial for understanding RCC progression and treatment response.
Purpose of the Study:
- To investigate the differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.
- To assess the prognostic value of TIM-3 expression in both primary and metastatic RCC.
Main Methods:
- Retrospective analysis of 163 RCC cases with metastases resected or biopsied.
- Immunohistochemical assessment of TIM-3 expression.
- Statistical analysis using SPSS, GraphPad Prism, and R software.
Main Results:
- TIM-3 was detected in 56.4% of cases, with a numerically higher rate in primary tumors (53.0%) than in metastases (42.6%).
- A statistically significant difference in TIM-3 expression was found between primary and metastatic sites (p=0.002), with poor concordance (Kappa=0.331).
- TIM-3 expression in both primary and metastatic tumors was associated with longer progression-free survival (PFS) and overall survival (OS), and improved predictive accuracy for survival models.
Conclusions:
- Significant differences in TIM-3 expression exist between primary and metastatic RCC.
- Analysis of metastatic sites may offer more accurate biological information for clinical decision-making and prognosis.
- The role of TIM-3 in RCC warrants further investigation due to controversial findings.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Conserved Binding Sites
Cell Specific Gene Expression
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites
iPS Cell Differentiation